The Present and FutureJACC State-of-the-Art ReviewUse of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review
JACC State-of-the-Art Review
Under an Elsevier user license
open archive
Central Illustration
Key Words
cardiovascular medications
gestation
pharmacokinetics
pregnancy
Abbreviations and Acronyms
AAD
antiarrhythmic medication
ACE
angiotensin-converting enzyme
ACOG
American Congress of Obstetricians and Gynecologists
AF
atrial fibrillation
AMD
alpha-methyldopa
ARB
angiotensin receptor blocker
ARNi
angiotensin receptor–neprysilin inhibitor
BAV
bicuspid aortic valve
CCB
calcium channel blocker
CVD
cardiovascular disease
ER
extraction ratio
ESC
European Society of Cardiology
FC
functional class
FDA
Food and Drug Administration
HCTZ
hydrochlorothiazide
IUGR
intrauterine fetal growth restriction
LMWH
low molecular weight heparin
MFS
Marfan syndrome
PH
pulmonary hypertension
PLLR
Pregnancy and Lactation Labeling Rule
PPCM
peripartum cardiomyopathy
QTc
QT interval corrected for heart rate
RV
right ventricular
SVT
supraventricular tachycardia
Vd
volume of distribution
VKA
vitamin K antagonist
VT
ventricular tachycardia
WPW
Wolff-Parkinson-White
Cited by (0)
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.
© 2019 by the American College of Cardiology Foundation. Published by Elsevier.